Spyre Therapeutics
SYRE
32 hedge funds and large institutions have $38.1M invested in Spyre Therapeutics in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
25% more capital invested
Capital invested by funds: $30.4M → $38.1M (+$7.69M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.03% less ownership
Funds ownership: 1.92% → 1.9% (-0.03%)
3% less funds holding
Funds holding: 33 → 32 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
+$104K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$50.6K |
| 3 |
VF
Virtu Financial
New York
|
+$48.5K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$37.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$653K |
| 2 |
Renaissance Technologies
New York
|
-$46.5K |
| 3 |
Jennison Associates
New York
|
-$43.5K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$13.6K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$9.84K |
SYRE Hedge Fund Activity: Q3 2017 in Review
32 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2017, worth a combined $38.1M — up 25% from $30.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SYRE and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 7 added.
The largest buyer was Spark Investment Management, adding an estimated $104K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $653K sold.
- 32 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2017, down from 33 in Q2 2017.
- Funds reported $38.1M of Spyre Therapeutics stock for Q3 2017, up 25% quarter-over-quarter.
- 4 funds opened new Spyre Therapeutics positions in Q3 2017 and 5 closed out, a net change of -1 holder.
- The largest Spyre Therapeutics buyer in Q3 2017 was Spark Investment Management, an estimated $104K added.
- The largest Spyre Therapeutics seller in Q3 2017 was Susquehanna International Group, an estimated $653K sold.
Based on aggregated 13F filings for Q3 2017.